Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study.

MLA

Huang, Zhenkun, et al. “Atezolizumab and Bevacizumab plus Transarterial Chemoembolization and Hepatic Arterial Infusion Chemotherapy for Patients with High Tumor Burden Unresectable Hepatocellular Carcinoma: A Multi-Center Cohort Study.” International Immunopharmacology, vol. 139, Sept. 2024, p. 112711. EBSCOhost, https://doi.org/10.1016/j.intimp.2024.112711.

APA

Huang, Z., Chen, T., Li, W., He, W., Liu, S., Wu, Z., Li, B., Yuan, Y., & Qiu, J. (2024). Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study. International Immunopharmacology, 139, 112711. https://doi.org/10.1016/j.intimp.2024.112711

Chicago

Huang, Zhenkun, Tiejun Chen, Wenbin Li, Wei He, Shaoru Liu, Zongfeng Wu, Binkui Li, Yunfei Yuan, and Jiliang Qiu. 2024. “Atezolizumab and Bevacizumab plus Transarterial Chemoembolization and Hepatic Arterial Infusion Chemotherapy for Patients with High Tumor Burden Unresectable Hepatocellular Carcinoma: A Multi-Center Cohort Study.” International Immunopharmacology 139 (September): 112711. doi:10.1016/j.intimp.2024.112711.